Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer

Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer is a phase 2, interventional study registered as NCT05969847 by 池畔, with a registry enrolment figure of 72 participants, started 2023-08-15 and due to reach its primary completion in 2027-12-31. Interventions recorded: split-course hypofraction radiotherapy; CAPOX; Envafolimab; Local excision. Conditions listed: Rectal Cancer. Primary outcome: Organ preservation. Colorectal eligibility wording from the registry: "Histopathology confirmed the rectal adenocarcinoma,cT3-4N0 or cT1-4N1-2". Sites: China. No results are recorded here; the registry entry is the source.